Abstract
The therapeutic approach based on anti-vascular endothelial growth factor (anti-VEGF) molecules can be used to treat two important complications of retinal dystrophies: choroidal neovascularization and macular edema. The macular involvement in retinal dystrophies can lead to further visual deterioration in patients at a young age and already affected by functional limitations. The study reports the effect of anti-VEGF treatment in several subforms of retinal dystrophies, critically discussing advantages and limitations.
Keywords:
Choroidal neovascularization; anti-VEGF; best vitelliform macular dystrophy; macular edema retinitis pigmentosa; pattern dystrophy; stargardt disease.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Choroidal Neovascularization / drug therapy
-
Choroidal Neovascularization / pathology
-
Humans
-
Macular Edema / drug therapy
-
Macular Edema / etiology
-
Retinal Dystrophies / complications
-
Retinal Dystrophies / drug therapy*
-
Retinal Dystrophies / pathology
-
Retinal Pigment Epithelium / drug effects
-
Retinitis Pigmentosa / complications
-
Retinitis Pigmentosa / drug therapy
-
Stargardt Disease / complications
-
Stargardt Disease / drug therapy
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
-
Vitelliform Macular Dystrophy / complications
-
Vitelliform Macular Dystrophy / drug therapy
-
Vitelliform Macular Dystrophy / pathology
Substances
-
Angiogenesis Inhibitors
-
Vascular Endothelial Growth Factor A